Meet our community: Bhavini Makwana
Bhavini was diagnosed with RP in 1997 aged 17. The consultant who confirmed her diagnosis told her that “there was no cure or treatment and she should prepare to go blind".
Search
Search results
Look Forward – Autumn 2025 – Issue 187
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
Look Forward – Winter 2025 – Issue 188
This is the final edition of Look Forward this year and what a year it has been! We’ve had some very positive feedback about our Conferences and the Big Give Christmas Challenge is back - a great opportunity to double your donation at no extra cost to you! We’ve included a handy ‘What’s on’ article which outlines some of our plans for 2026. We would like to take this opportunity to wish all of our readers a very Merry Christmas and a happy and fulfilling New Year.
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
Research round-up, spring 2023
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
e-Newsletter October 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Podcast: What is the UKIRDC and why does it exist?
With a significant proportion of inherited retinal conditions being caused by unidentified genetic faults, and many families unable to get clear results from genetic tests in clinic, the project set out to solve previously undiagnosable cases and discover more of the genes and mutations that are associated with sight loss.
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Genetic testing: an essential topic for discussion with the IRD community
As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.
Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.